ID   cFA404-KiPS4F-3
AC   CVCL_C193
SY   cFA404-KiPS4F3; KiPS4F3; ESi005-B; ESi029-A
DR   hPSCreg; ESi005-B
DR   ISCR; 2268
DR   SKIP; SKIP002385
DR   Wikidata; Q54811422
RX   PubMed=19483674;
WW   https://p-cmrc.cat/wp-content/uploads/2020/06/Documento_Deposito_Lineas_cFA404-KiPS4F-3_DEF.pdf
WW   https://www.isciii.es/QueHacemos/Servicios/BIOBANCOS/BNLC/Lists/Lneas%20iPS/Attachments/27/Caracteristicas%20-%20Linea_cFA404-KiPS4F-3_DEF.pdf
WW   https://www.isciii.es/QueHacemos/Servicios/BIOBANCOS/BNLC/Lists/Lneas%20iPS/Attachments/27/Anexo%20-%20Anexo_cFA404-KiPS4F3_def.pdf
CC   Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection.
CC   From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain.
CC   HLA typing: A*02,24; B*35,51; C*02,04; DQB1*02,03; DRB1*03,04 (BNLC).
CC   Transfected with: HGNC; 3582; FANCA.
CC   Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP).
CC   Derived from site: In situ; Skin, epidermis; UBERON=UBERON_0001003.
CC   Cell type: Keratinocyte; CL=CL_0000312.
ST   Source(s): PubMed=19483674
ST   Amelogenin: X,Y
ST   D13S317: 12,13
ST   D18S51: 14,15
ST   D21S11: 27,29
ST   D3S1358: 15,16
ST   D5S818: 11,13
ST   D7S820: 10,13
ST   D8S1179: 14,15
ST   FGA: 19,25
ST   vWA: 14,18
DI   NCIt; C125702; Fanconi anemia, complementation group A
DI   ORDO; Orphanet_84; Fanconi anemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C192 ! cFA404-KiPS4F-1
SX   Male
AG   Age unspecified
CA   Induced pluripotent stem cell
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 20
//
RX   PubMed=19483674; DOI=10.1038/nature08129;
RA   Raya A., Rodriguez-Piza I., Guenechea G., Vassena R., Navarro S.,
RA   Barrero M.J., Consiglio A., Castella M., Rio P., Sleep E.,
RA   Gonzalez F., Tiscornia G., Garreta E., Aasen T., Veiga A., Verma I.M.,
RA   Surralles J., Bueren J., Izpisua Belmonte J.C.;
RT   "Disease-corrected haematopoietic progenitors from Fanconi anaemia
RT   induced pluripotent stem cells.";
RL   Nature 460:53-59(2009).
//